Skip to content

Study · Randomized controlled trial · n = 6 · 2001

5 results

Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.

Gianotti L, Ramunni J, Lanfranco F, Maccagno B, Giordano R, Broglio F, Maccario M, Muller EE, Ghigo E, Arvat E

Journal of endocrinological investigation1 Feb 2001Cited by 9 (Europe PMC)

PMID11263473 (opens in a new tab)DOI10.1007/bf03343815 (opens in a new tab)PepBankPUB-11263473
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In normal young women, hexarelin raised ACTH from baseline, with a response similar to that of hCRH.

    In plain wordsIn healthy young women, hexarelin raised ACTH, a response similar to that of CRH.

    Peptide
    Hexarelin
    Outcome
    IncreaseACTH response to hexarelin
    Study

    n = 6

    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2.0 microg/kg · intravenousAs given in this study (human).

    Measurements

    ACTH peak
    30.3 pg/ml
    hexarelin
    ACTH baseline
    19.2 pg/ml
    hexarelin

    Source sentences

    Summary
    CRH and HEX induced similar ACTH (peak vs baseline, mean+/-SE: 47.5+/-10.9 vs 21.3+/-3.0 pg/ml and 30.3+/-6.9 vs 19.2+/-3.8 pg/ml, respectively; p<0.04) and cortisol responses (177.5+/-5.4 vs 109.3+/-10.3 microg/l and 149.4+/-12.3 vs 119.8+/-16.4 microg/l, respectively, p<0.04).
    2 context sentences
    Summary · context
    We studied the effect of rhIGF-I (recombinant human IGF-I; 20 microg/kg s.c. at -180 min) or placebo on the ACTH and cortisol responses to hCRH (human CRH; 2.0 microg/kg i.v. at 0 min) or hexarelin (HEX; 2.0 microg/kg i.v. at 0 min), a peptidyl GHS, in normal young women.
    Summary · context
    The subjects were six normal young women [age: 26-35 yr; body mass index (BMI): 19-23 kg/m2] in their early follicular phase.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In normal young women, hexarelin raised cortisol from baseline, with a response similar to that of hCRH.

    In plain wordsIn healthy young women, hexarelin raised cortisol, a response similar to that of CRH.

    Peptide
    Hexarelin
    Outcome
    IncreaseCortisol response to hexarelin
    Study

    n = 6

    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2.0 microg/kg · intravenousAs given in this study (human).

    Measurements

    Cortisol peak
    149.4 microg/l
    hexarelin
    Cortisol baseline
    119.8 microg/l
    hexarelin

    Source sentences

    Summary
    CRH and HEX induced similar ACTH (peak vs baseline, mean+/-SE: 47.5+/-10.9 vs 21.3+/-3.0 pg/ml and 30.3+/-6.9 vs 19.2+/-3.8 pg/ml, respectively; p<0.04) and cortisol responses (177.5+/-5.4 vs 109.3+/-10.3 microg/l and 149.4+/-12.3 vs 119.8+/-16.4 microg/l, respectively, p<0.04).
    2 context sentences
    Summary · context
    We studied the effect of rhIGF-I (recombinant human IGF-I; 20 microg/kg s.c. at -180 min) or placebo on the ACTH and cortisol responses to hCRH (human CRH; 2.0 microg/kg i.v. at 0 min) or hexarelin (HEX; 2.0 microg/kg i.v. at 0 min), a peptidyl GHS, in normal young women.
    Summary · context
    The subjects were six normal young women [age: 26-35 yr; body mass index (BMI): 19-23 kg/m2] in their early follicular phase.

Studies that did not test the peptide alone3

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 03HumanNot a test of Hexarelin aloneRandomized controlled trialEfficacy outcome

    In normal young women, rhIGF-I pretreatment did not change the ACTH response to hexarelin.

    In plain wordsIn healthy young women, IGF-I pretreatment did not change the ACTH rise caused by hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeACTH response to hexarelin after rhIGF-I
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Pituitary hormones · Endocrine and hormones

    Measurements

    ACTH response to hexarelin after rhIGF-I
    28.8 pg/ml
    rhIGF-I pretreatment

    Source sentences

    Summary
    RhIGF-I pretreatment did not modify the ACTH and cortisol responses to hCRH (46.0+/-13.8 pg/ml and 181.1+/-16.9 microg/l, respectively) as well as those to HEX (28.8+/-5.0 pg/ml and 144.1+/-16.2 microg/l, respectively).
    2 context sentences
    Summary · context
    We studied the effect of rhIGF-I (recombinant human IGF-I; 20 microg/kg s.c. at -180 min) or placebo on the ACTH and cortisol responses to hCRH (human CRH; 2.0 microg/kg i.v. at 0 min) or hexarelin (HEX; 2.0 microg/kg i.v. at 0 min), a peptidyl GHS, in normal young women.
    Summary · context
    The subjects were six normal young women [age: 26-35 yr; body mass index (BMI): 19-23 kg/m2] in their early follicular phase.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 04HumanNot a test of Hexarelin aloneRandomized controlled trialEfficacy outcome

    In normal young women, rhIGF-I pretreatment did not change the cortisol response to hexarelin.

    In plain wordsIn healthy young women, IGF-I pretreatment did not change the cortisol rise caused by hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeCortisol response to hexarelin after rhIGF-I
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Pituitary hormones · Endocrine and hormones

    Measurements

    Cortisol response to hexarelin after rhIGF-I
    144.1 microg/l
    rhIGF-I pretreatment

    Source sentences

    Summary
    RhIGF-I pretreatment did not modify the ACTH and cortisol responses to hCRH (46.0+/-13.8 pg/ml and 181.1+/-16.9 microg/l, respectively) as well as those to HEX (28.8+/-5.0 pg/ml and 144.1+/-16.2 microg/l, respectively).
    2 context sentences
    Summary · context
    We studied the effect of rhIGF-I (recombinant human IGF-I; 20 microg/kg s.c. at -180 min) or placebo on the ACTH and cortisol responses to hCRH (human CRH; 2.0 microg/kg i.v. at 0 min) or hexarelin (HEX; 2.0 microg/kg i.v. at 0 min), a peptidyl GHS, in normal young women.
    Summary · context
    The subjects were six normal young women [age: 26-35 yr; body mass index (BMI): 19-23 kg/m2] in their early follicular phase.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  3. 05HumanNot a test of Hexarelin aloneRandomized controlled trialEfficacy outcome

    In normal young women, rhIGF-I pretreatment reduced the GH response to hexarelin versus placebo.

    In plain wordsIn healthy young women, IGF-I pretreatment reduced the growth hormone rise caused by hexarelin, compared with placebo.

    Peptide
    Hexarelin
    Outcome
    DecreaseGH response to hexarelin after rhIGF-I
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH response to hexarelin after rhIGF-I
    23.9 microg/l
    rhIGF-I
    GH response to hexarelin after placebo
    64.7 microg/l
    placebo

    Source sentences

    Summary
    On the other hand, the GH response to HEX was clearly reduced by rhIGF-I (23.9+/-4.7 vs 64.7+/-14.8 microg/l, p<0.05).
    2 context sentences
    Summary · context
    We studied the effect of rhIGF-I (recombinant human IGF-I; 20 microg/kg s.c. at -180 min) or placebo on the ACTH and cortisol responses to hCRH (human CRH; 2.0 microg/kg i.v. at 0 min) or hexarelin (HEX; 2.0 microg/kg i.v. at 0 min), a peptidyl GHS, in normal young women.
    Summary · context
    The subjects were six normal young women [age: 26-35 yr; body mass index (BMI): 19-23 kg/m2] in their early follicular phase.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.